Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposure. During the placebo-controlled 12-week induction period, rates of serious adverse events per 100 patient-years were 10.8 and 9.6 (brodalumab 140 mg and 210 mg, respectively) vs 4.3 and 6.5 (ustekinumab and placebo, respectively); infections were the most frequent serious adverse event. Rates of serious adverse events during the comparator-controlled 52-week period were 14.4, 10.2 and 8.3 per 100 patient-years for brodalumab 210 mg, brodalumab 140 mg, and ustekinumab, respectively. Brodalumab was not associated with increased risks of malignancy, major adverse cardiac events, suicidal ideation and behaviour, or fatal events. Overall, brodalumab demonstrated an acceptable safety profile in short- and long-term treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574679 | PMC |
| http://dx.doi.org/10.2340/actadv.v102.1993 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.
Int Arch Allergy Immunol
December 2024
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- The study investigates the safety of various biologics used for psoriasis during pregnancy, highlighting that data on risks is lacking outside of TNF-α inhibitors.
- Using the WHO global pharmacovigilance database, researchers analyzed over 6,500 reports of pregnancy-related adverse outcomes and compared them among different biologics.
- The findings indicate that most biologics have a lower frequency of adverse pregnancy-related outcomes compared to TNF-α inhibitors, except for brodalumab, while risankizumab showed a higher incidence of abortion and stillbirth.
Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.
Int J Dermatol
July 2024
Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
Background: Brodalumab is a monoclonal antibody and IL-17 RA inhibitor that is approved for the treatment of moderate-to-severe psoriasis. The present study aims to estimate the drug survival (DS), effectiveness, and safety of brodalumab over a period of 156 weeks.
Methods: The primary objectives were: (i) to determine the treatment response rate at Weeks 16, 28, 52, 78, 104, and 156 as defined by PASI100, PASI90, and an absolute PASI ≤ 3 and (ii) long-term DS.
Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis.
Value Health
April 2023
Kielo Research, Zug, Switzerland.
Objectives: Quantitative benefit-risk assessment (qBRA) is a structured process to evaluate the benefit-risk balance of treatment options to support decision making. The ISPOR qBRA Task Force was recently established to provide recommendations for the design, conduct, and reporting of qBRA. This report presents a hypothetical case study illustrating how to apply the Task Force's recommendations toward a qBRA to inform the benefit-risk assessment of brodalumab at the time of initial marketing approval.
View Article and Find Full Text PDFSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev
May 2022
Department of Dermatology, Hôpital Henri Mondor, Créteil, France.
Article Synopsis
- - Psoriasis is a chronic disease with symptoms affecting the skin and joints, significantly lowering quality of life; while no cure exists, various treatment options help manage symptoms.
- - This study aims to evaluate the efficacy and safety of different psoriasis treatments (including systemic agents and biologics) through a network meta-analysis to determine their effectiveness and rank them accordingly.
- - The researchers reviewed randomized controlled trials involving adults with moderate-to-severe psoriasis, focusing on outcomes like skin improvement and serious adverse events to assess treatment effectiveness and safety.
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
August 2022
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK.
Background: Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided high levels of skin clearance through 52 weeks in patients with moderate-to-severe psoriasis and was generally well tolerated.
Objectives: To assess efficacy response rates and safety outcomes through 120 weeks for patients with moderate-to-severe psoriasis who received brodalumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!